Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00439543
Status:
UNKNOWN
Last Update Posted:
2007-02-23
First Post:
2007-02-22
Brief Title:
Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
Sponsor:
Interstitial Lung Disease Study Group Korea
Organization:
Interstitial Lung Disease Study Group Korea
Study Overview
Official Title:
Inhaled Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
Status:
UNKNOWN
Status Verified Date:
2007-02
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Idiopathic pulmonary fibrosisIPF is chronic progressive fibrosing lung disease of unknown cause There is no effective therapy yet for this disease and the mean survival in most reports is about 3 years after the diagnosis Because of the stiff fibrosis of the lung pulmonary hypertension is the late complication of IPF and its development heralds a very poor outcome of the patients For the primary pulmonary hypertension recently the effective drugs have been available However there is no study about the efficacy of these drugs in the patients with pulmonary hypertension secondary to pulmnary fibrosis and the aim of this trial is to study the safty and efficacy of Iloprost one of the safe and effective drugs in primary pulmonary hypertension
Detailed Description:
Prospective open labeled observational study
Subjects About 15 patients with secondary pulmonary hypertension due to IPF or pulmonary fibrosis associated with collagen vascular diseases
Method 3 month trial of inhaled iloprost Check the safty and measure the pulmonary arterial pressure by right heart catheterization exercise capacity by 6 minute walking test echocardiography and quality of life questionnaires before and after the trial
Subjects About 15 patients with secondary pulmonary hypertension due to IPF or pulmonary fibrosis associated with collagen vascular diseases
Method 3 month trial of inhaled iloprost Check the safty and measure the pulmonary arterial pressure by right heart catheterization exercise capacity by 6 minute walking test echocardiography and quality of life questionnaires before and after the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None